Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study
暂无分享,去创建一个
A. Butte | B. Pulendran | H. Hedlin | J. Andrews | C. Blish | M. Holubar | B. Greenhouse | I. Rodríguez-Barraquer | G. Tan | J. Parsonnet | Taia T. Wang | Zicheng Hu | P. Jagannathan | C. Khosla | A. Subramanian | H. Bonilla | S. Chakraborty | U. Singh | K. van der Ploeg | K. Jacobson | M. Ty | Saki Takahashi | Y. Maldonado | P. Arunachalam | L. de la Parte | K. Press | D. A. Mori
[1] J. Andrews,et al. TNF-α+ CD4+ T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies , 2022, Cell Reports Medicine.
[2] Mark M. Davis,et al. Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity , 2022, Science Translational Medicine.
[3] H. Hedlin,et al. Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial , 2021, medRxiv.
[4] Michael I. Mandel,et al. Waning Immunity after the BNT162b2 Vaccine in Israel , 2021, The New England journal of medicine.
[5] Mark M. Davis,et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans , 2021, Nature.
[6] L. Nolen,et al. COVID-19 Vaccine Breakthrough Infections Reported to CDC — United States, January 1–April 30, 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[7] Lucas T. Graybuck,et al. Longitudinal immune dynamics of mild COVID-19 define signatures of recovery and persistence , 2021, bioRxiv.
[8] Shenmin Zhang,et al. Divergent early antibody responses define COVID-19 disease trajectories , 2021, bioRxiv.
[9] A. Takaoka,et al. RIG-I triggers a signaling-abortive anti-SARS-CoV-2 defense in human lung cells , 2021, Nature Immunology.
[10] Frances E. Muldoon,et al. Single-cell multi-omics analysis of the immune response in COVID-19 , 2021, Nature Medicine.
[11] M. Davenport,et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19 , 2021, Nature communications.
[12] Xiang Wang. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. , 2021, The New England journal of medicine.
[13] W. Lau,et al. Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19 , 2021, Cell.
[14] J. Glenn,et al. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial , 2021, The Lancet Respiratory Medicine.
[15] Bjoern Peters,et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.
[16] K. Blennow,et al. Proteomic blood profiling in mild, severe and critical COVID-19 patients , 2020, Scientific Reports.
[17] T. Tabuchi,et al. Coronavirus Disease , 2021, Encyclopedia of the UN Sustainable Development Goals.
[18] Aaron J. Wilk,et al. Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19 , 2020, bioRxiv.
[19] J. Casanova,et al. Life-Threatening COVID-19: Defective Interferons Unleash Excessive Inflammation , 2020, Med.
[20] L. Notarangelo,et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients , 2020, JCI insight.
[21] H. Hedlin,et al. Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial , 2020, Nature Communications.
[22] L. Carter,et al. Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19 , 2020, Cell.
[23] S. Ladhani,et al. Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection , 2020, bioRxiv.
[24] A. Casto,et al. Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection , 2020, The Journal of infectious diseases.
[25] Barbara B. Shih,et al. Genetic mechanisms of critical illness in COVID-19 , 2020, Nature.
[26] K. To,et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] Madeleine K. D. Scott,et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans , 2020, Science.
[28] Alexander Sczyrba,et al. Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment , 2020, Cell.
[29] Eric Song,et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19 , 2020, Nature.
[30] Yang Wu,et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19 , 2020, Nature Communications.
[31] Laura J. Simpson,et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19 , 2020, Nature Medicine.
[32] Akiko Iwasaki,et al. Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19 , 2020, Cell Host & Microbe.
[33] G. Gao,et al. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19 , 2020, Journal of Allergy and Clinical Immunology.
[34] Nathaniel Hupert,et al. Clinical Characteristics of Covid-19 in New York City , 2020, The New England journal of medicine.
[35] Zunyou Wu,et al. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.
[36] A. Butte,et al. xCell: digitally portraying the tissue cellular heterogeneity landscape , 2017, bioRxiv.
[37] A. Egli,et al. Interferon Lambda: Modulating Immunity in Infectious Diseases , 2017, Front. Immunol..
[38] K. Rajarathnam,et al. Chemokine CXCL1 mediated neutrophil recruitment: Role of glycosaminoglycan interactions , 2016, Scientific Reports.
[39] Alexey Sergushichev,et al. An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation , 2016 .
[40] G. Sutter,et al. CCL2 expression is mediated by type I IFN receptor and recruits NK and T cells to the lung during MVA infection , 2016, Journal of leukocyte biology.
[41] Lior Pachter,et al. Near-optimal probabilistic RNA-seq quantification , 2016, Nature Biotechnology.
[42] J. Erjefält,et al. The neutrophil-recruiting chemokine GCP-2/CXCL6 is expressed in cystic fibrosis airways and retains its functional properties after binding to extracellular DNA , 2015, Mucosal Immunology.
[43] G. von Heijne,et al. Tissue-based map of the human proteome , 2015, Science.
[44] Sandra Romero-Steiner,et al. Molecular signatures of antibody responses derived from a systems biological study of 5 human vaccines , 2013, Nature Immunology.
[45] Herwig P. Moll,et al. The differential activity of interferon-α subtypes is consistent among distinct target genes and cell types , 2011, Cytokine.
[46] Christopher J. Obara,et al. Chemokine Receptor Ccr2 Is Critical for Monocyte Accumulation and Survival in West Nile Virus Encephalitis , 2011, The Journal of Immunology.
[47] T. Matsumiya,et al. Function and regulation of retinoic acid-inducible gene-I. , 2010, Critical reviews in immunology.
[48] Yi Li,et al. Type I interferon modulates monocyte recruitment and maturation in chronic inflammation. , 2009, The American journal of pathology.
[49] E. Pamer. Tipping the balance in favor of protective immunity during influenza virus infection , 2009, Proceedings of the National Academy of Sciences.
[50] S. Dower,et al. Acceleration of Human Neutrophil Apoptosis by TRAIL1 , 2003, The Journal of Immunology.
[51] Ming Xu,et al. DNA fragmentation in apoptosis , 2000, Cell Research.
[52] T. Ley,et al. DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis. , 2000, Immunity.
[53] R. Bravo,et al. Defects in Macrophage Recruitment and Host Defense in Mice Lacking the CCR2 Chemokine Receptor , 1997, The Journal of experimental medicine.
[54] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .